Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

Notably, the company had already taken steps to make SYMBICORT more accessible by substantially reducing its list price ... This expansion of AstraZeneca’s savings programs arrives at a critical ...